Precision at the electrode: a decade of directional neurostimulation, validated in humans
Precision at the electrode: a decade of directional neurostimulation, validated in humans
Precision at the electrode: a decade of directional neurostimulation, validated in humans
Aleva built a MEMS-based directional neuromodulation platform from the ground up, from electrode design to human clinical data. The lead architecture and manufacturing know-how are now available to partners through structured licensing, tech transfer and selective co-development.
Aleva built a MEMS-based directional neuromodulation platform from the ground up, from electrode design to human clinical data. The lead architecture and manufacturing know-how are now available to partners through structured licensing, tech transfer and selective co-development.
Aleva built a MEMS-based directional neuromodulation platform from the ground up, from electrode design to human clinical data. The lead architecture and manufacturing know-how are now available to partners through structured licensing, tech transfer and selective co-development.
The Differentiation Is in the Lead
The Differentiation Is in the Lead
Aleva's MEMS-based directional lead combines 12 fully independent contacts, rounded electrode geometry and lower CT/MRI artefact to support precise field shaping and electrode-level control. Developed and validated within the complete directSTIM system, the lead architecture and the manufacturing know-how behind it are what Aleva licenses.
Aleva's MEMS-based directional lead combines 12 fully independent contacts, rounded electrode geometry and lower CT/MRI artefact to support precise field shaping and electrode-level control. Developed and validated within the complete directSTIM system, the lead architecture and the manufacturing know-how behind it are what Aleva licenses.
Validated in Humans
Validated in Humans
Aleva’s directional neuromodulation platform is supported by human clinical data and published directional stimulation research. The evidence points to symptom improvement, medication reduction and a wider therapeutic window for directional stimulation.
Aleva’s directional neuromodulation platform is supported by human clinical data and published directional stimulation research. The evidence points to symptom improvement, medication reduction and a wider therapeutic window for directional stimulation.
48% Symptom Improvement
With stimulation on, medication off (UPDRS III) — PMCF
63% Medication
Reduction
At 6 months, post-market follow-up (LEDD) — PMCF
41.3% Wider Therapeutic Window
Directional vs omnidirectional
Brain, Oxford Academic, 2014
100 Granted
Patents
Across 10+ patent families,
protected IP portfolio
A Platform Built for Licensing and Partnerships
A Platform Built for Licensing and Partnerships
Aleva's MEMS-based directional lead architecture can be licensed by patent family or interface module. Partners can start with a defined indication, interface or territory, then expand scope over time. Manufacturing know-how transfer and access to Aleva's EPFL-rooted technical expertise are available under tech transfer and co-development engagements.
Aleva's MEMS-based directional lead architecture can be licensed by patent family or interface module. Partners can start with a defined indication, interface or territory, then expand scope over time. Manufacturing know-how transfer and access to Aleva's EPFL-rooted technical expertise are available under tech transfer and co-development engagements.
The Differentiation
Is in the Lead
The Differentiation
Is in the Lead
Aleva's MEMS-based directional lead combines 12 fully independent contacts, rounded electrode geometry and lower CT/MRI artefact to support precise field shaping and electrode-level control. Developed and validated within the complete directSTIM system, the lead architecture and the manufacturing know-how behind it are what Aleva licenses.
Aleva's MEMS-based directional lead combines 12 fully independent contacts, rounded electrode geometry and lower CT/MRI artefact to support precise field shaping and electrode-level control. Developed and validated within the complete directSTIM system, the lead architecture and the manufacturing know-how behind it are what Aleva licenses.
A Platform Built for Licensing and Partnerships
Aleva's MEMS-based directional lead architecture can be licensed by patent family or interface module. Partners can start with a defined indication, interface or territory, then expand scope over time. Manufacturing know-how transfer and access to Aleva's EPFL-rooted technical expertise are available under tech transfer and co-development engagements.
Validated in Humans
Aleva’s directional neuromodulation platform is supported by human clinical data and published directional stimulation research. The evidence points to symptom improvement, medication reduction and a wider therapeutic window for directional stimulation.
48% Symptom Improvement
With stimulation on, medication off
(UPDRS III) — PMCF
63% Medication Reduction
At 6 months, post-market follow-up
(LEDD) — PMCF
41.3% Wider Therapeutic Window
Directional vs omnidirectional
Brain, Oxford Academic, 2014
100 GrantedPatents
Across 10+ patent families,
protected IP portfolio